The Bench to Bottle™ Partnership Model

The Bench to Bottle™ Partnership Model

Bench to Bottle™ is our partnership model for supporting the full veterinary vaccine lifecycle. By aligning research, development, manufacturing, and regulatory perspectives from the start, it helps reduce handoffs, improve decision-making, and address downstream requirements earlier in development

In practice, partners can engage HRA for a specific stage of development or for end-to-end support. Throughout the program, teams keep manufacturing feasibility and regulatory expectations in view to support smoother execution..

Integrated Support Across the Vaccine Lifecycle

Research and Development Collaboration

HRA partners with organizations at various stages, from early-stage concepts to late-stage optimization, providing applied scientific support to generate meaningful, decision-ready data. Key collaboration areas include:

• Biological and immunological assay development
• In vitro test development 
• Lab animal and host animal challenge model development

Process Development and Technical Scale-Up

As programs progress, HRA supports robust, scalable, and transferable process design and optimization, including technology transfer planning and scale-up readiness for licensed products. This can be especially valuable for teams preparing for U.S. licensure or transferring products developed outside the United States.

Manufacturing Support, With Flexibility

HRA provides flexible manufacturing support that can be completed at HRA facilities or transitioned to a partner site following process development, helping maintain continuity between development and production.

Regulatory Perspective Embedded Early

Regulatory considerations are integrated throughout HRA’s approach, supported by scientific experience working with the USDA, helping teams align development strategies with U.S. regulatory expectations and reduce regulatory risk and uncertainty.

Experience and Stability You Can Build On

HRA was established in 2001 by Kristina J. Hennessy, DVM, PhD, Diplomate ACVM (Immunology), and is founded on principles of scientific rigor and regulatory integrity.

As part of Kemin, a family-owned company founded in Iowa in 1961, HRA benefits from long-term investment, global infrastructure, and established quality systems, supporting continuity as programs grow and scale.

Ready to Move Forward?

Share your program stage and what you need next. We will connect you with the right HRA specialists.